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Asthma is a complex genetic disorder involving the interplay between various environmental and
genetic factors. In this review, efforts have been made to provide information on the recent advances in
these areas and to discuss the future perspective of research in the area of developing personalized
drugs using pharmacogenomic approach. Atopic asthma is found to be strongly familial, however the
mode of inheritance is controversial. A large number of studies have been carried out and a number of
candidate genes have been identified. In addition, a number of chromosomal regions have been identified
using genome-wide scans, which might contain important unknown genes. It has been shown in studies
carried out in different populations that the genetic predisposition varies with ethnicity. In other
words, genes that are associated with asthma in one population may not be associated with asthma in
another population. In addition to the involvement of multiple genes, gene-gene interactions play a
significant role in asthma. The importance of environmental factors in asthma is beyond doubt. However,
it remains controversial whether a cleaner environment or increased pollution is a trigger for asthma.
Despite the increasing prevalence of the disorder, only a limited number of therapeutic modalities are
available for the treatment. A number of novel therapeutic targets have been identified and drugs are
being developed for better efficacy with less side-effects. With the rapid progress in the identification
of genes involved in various ethnic populations combined with the availability in future of well-targeted
drugs, it will be possible to have appropriate medicine as per the genetic make-up of an individual.
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particularly eosinophils, into the lungs and release
of vasoactive mediators from mast cells set the stage
for asthmatic inflammation. Two functional
alterations are typically associated with asthma.
These include variable airway obstruction and
bronchial hyperresponsiveness. The narrowing of
the airways is associated with smooth muscle
contraction, airway wall thickening, oedema and
increased mucus secretion1 ,2. Along with these,
there is denudation of the airway epithelium and
collagen deposition beneath the basement
membrane3. Several quantitative traits are associated
Review  Article
Asthma is a chronic inflammatory disorder of the
airways of the lungs. Many cells and cellular
elements, including mast cells, eosinophils,
T-lymphocytes, macrophages, neutrophils and
epithelial cells are involved in the process. The
inflammation causes recurrent episodes of wheezing,
breathlessness, chest tightness, and coughing in
susceptible individuals, particularly in the night or
early in the morning1. These episodes are usually
associated with widespread but variable airflow
obstruction that is reversible either spontaneously or
with treatment. The infiltration of leukocytes,
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with the asthma phenotype. These include forced
expiratory volume in one second (FEV1), forced vital
capacity (FVC), airway hyperresponsiveness by
methacholine challenge, serum total immunoglobulin
E (IgE), serum immunoglobulin E specific to certain
allergens, eosinophil counts in the peripheral blood,
and skin prick test to a panel of locally predominant
environmental allergens4-6.
Studies over the last 25 years have clearly
demonstrated that both genetic and environmental
factors determine the phenotypic expression of
asthma7. It affects nearly 155 million individuals the
world-over8. In an epidemiological study conducted
in India, approximately 10-15 per cent of the Indian
population, particularly women and children (under
5 yr of age), were found to be affected by atopic
asthma9. It has been estimated that around 34 per
cent of the total man-days lost are due to asthma
and other airway disorders9. The rising incidence of
asthma over the past decades suggests that
environmental and lifestyle factors are important8.
Biochemical pathways involved in the pathogenesis
of asthma
The biochemical pathways involving atopic
asthma have been studied in great detail. Basically,
two types of airway responses are initiated on
allergen challenge of an appropriately sensitized
asthmatic individual10. The early phase is
characterized with an acute bronchospasmatic event
that begins 15-30 min after exposure and resolves
over time. The process initiates with the recruitment
of a subtype of CD4+ T cells, Th2, which produce
predominantly interleukin-4 (IL-4), interleukin-5
(IL-5) and interleukin-13 (IL-13)), at the site of
immune activation10,11 . IL-4 along with IL-13
induces B cells to produce immunoglobulin E
(IgE)12,13. IL-13 also induces mucus secretion from
the goblet cells 14,15. IL-5 in association with
interleukin-3 (IL-3) and granulocyte-monocyte
colony stimulating factor (GMCSF) helps
eosinophils to grow, mature and infiltrate into the
lungs16-18. Thus, asthma is mainly associated with
an increase in Th2 cytokines both in the
broncoalveolar lavage (BAL) and serum and with
increased IgE levels in the sera19,20. Crosslinking of
IgE receptor present on mast cells by fresh exposure
of allergens initiates this acute phase. The late phase
response begins 4-6 h after the initial insult and
causes prolonged symptomology. The infiltration of
leukocytes, particularly eosinophils, into the lungs
and release of vasoactive mediators from mast cells
set the stage for asthmatic inflammation20. Along
with cytokines, chemokines play a major role in
asthma pathogenesis as they are potent leukocyte
chemoattractants, cell activating factors, and
histamine-releasing factors. In particular, the eotaxin
subfamily of chemokines and their receptor CC
chemokine receptor 3 (CCR3) have emerged as
central regulators of the asthmatic response21,22.
Recent studies have provided an integrated
mechanism for understanding the coordinate
interaction between IL-13 and chemokines in the
pathogenesis of asthma 23. Finally, structural
alterations, including airway wall thickening, lung
fibrosis, mucus metaplasia, hyperplasia and
hypertrophy of the myocyte are certain features
which are generally observed in the airway of
asthmatics2 ,3.
Contribution of genes in the pathogenesis of asthma
Asthma is a complex disorder of multi-factorial
origin. Atopic asthma in children is found to be
strongly familial and a genetic basis is indicated by
familial aggregation and the identification of
candidate genes and chromosomal regions linked to
asthma risk24. The risk of a first-degree relative of
an asthmatic individual being asthmatic is two to
almost six times higher than the risk for an
individual from the general population to develop
the disease24-26.  Both shared genes and shared
environment account for such a huge risk. Twin
studies have shown that the incidence of asthma is
significantly higher in monozygotic twins than
dizygotic twins27-29. It has earlier been shown that
atopic asthma was influenced by a few genes with
moderate effects30. Similarly few other studies have
implicated the maternal inheritance of atopy31. A
previous study has suggested that early breast-
feeding may increase the risk of allergic disease in
genetically susceptible  children32.
Although asthma has a significant heritable
component, the mode of inheritance is controversial
due to the complex nature of the disorder. In a study
conducted in Taiwan, it was concluded that a history
of asthma in parents is a strong risk factor for asthma
in the offspring33. Under the assumption of applied
segregation, it was reported that at least one major
gene exists that could be involved in the
development of allergy. In addition, a polygenic/
multifactorial (genetic and environmental factors)
influence with a recessive component inheritance
may be involved in the pathogenesis of asthma33.
Further, there are gene-gene interactions that may
lead to increased risk of developing asthma8,34,35.
Polymorphisms in several candidate genes have
been found to be associated with asthma and allergic
disorders (Table I). Atopy was linked to a genetic
marker on chromosome 11q1336,37. In different
independent studies, polymorphism in the beta chain
of high-affinity receptor for IgE (FceRI-b) in the
same chromosomal location was found to be
associated with asthma, atopy, bronchial hyper-
responsiveness and severe atopic dermatitis37,38.  A
significant association of total serum IgE
concentrations and asthma with genetic markers
within the IL4  gene cluster (5q31.1) has been
established39,40. Interestingly, this region, contains a
large number of important candidate genes that
encode IL4, IL13, IRF1, IL9, CD14, IL-12b and
b2-adrenergic receptor39. Recently, polymorphisms
have been recognised in several of these genes which
may contribute to the pathophysiology of allergic
diseases41,42. It has been proposed that these genes
are co-ordinately expressed due to the presence of
some common regulatory motifs, therefore,
polymorphisms within this cluster could be due to
linkage disequilibrium with other known or unknown
genes39. In a preliminary study conducted in the
Indian population, it has been observed that
polymorphisms in the proximal promoter and a CA
repeat in intron 2 of IL4  are less likely to be
associated with asthma (Nagarkatti and Ghosh,
unpublished data).
Chromosome 12q is another interesting region for
both asthma and atopy because of the presence of
several candidate genes encoding IFN-g43,44, signal
transducer and activator of transcription
(STAT6) 45-49, a mast cell growth factor and a
b-subunit of nuclear factor-Y. Studies with Afro-
Caribbean and Caucasian populations found an
association of serum IgE and asthma to markers on
chromosome 12q50. Earlier studies in several
populations have observed that IFN-g gene was
linked to atopy and asthma 43,44. Recent studies
carried out in the Indian population have shown a
significant positive association of (CA)n repeat in
IFN-g with asthma phenotype and serum IgE
levels43. STAT-6 plays a major role in the initiation
of signals from activated Th2 cells, specifically
through IL-4 and IL-13 receptors48. In a study
conducted in the Indian population, novel
polymorphisms in the STAT6 gene had been
identified51. Using a novel CA repeat region in the
proximal promoter region [denoted as R1] and a
previously identified CA repeat in the 5'-UTR
[denoted as R3], it has been demonstrated that a
haplotype, containing 17 CA repeats at the R1 locus
and 15 CA repeats at the R3 locus was significantly
associated with asthma in the Indian population
(Nagarkatti and Ghosh, unpublished data).
A polymorphism in the IL4Ra  coding region has
been associated with asthma52. Also, polymorphism
in TNF-a  has been found to be associated with
asthma 53. An increased risk of aspirin-induced
asthma is found to be associated with polymorphism
in the leukotrine C4 synthase (LTC4S) promoter54.
There is a significant difference in the linkage in
candidate genes among various ethnic populations.
Studies of asthma conducted in Japan, UK, and USA
have implicated chromosome 5q as the region
containing one or more susceptibility genes for
asthma 55-58 . However, in studies conducted in
Australian, Finnish, British, Scottish and German
populations, chromosome 5q did not be appeared to
be linked with asthma or atopy59-63. These studies
on candidate genes have been mostly done on limited
sample sizes. For the utility of these studies a large-
scale epidemiological study is required to classify
various classes of allergies and asthma.
In addition to studies on candidate genes, several
genome-wide searches have been carried out. In this
approach, genetic markers throughout the genome
are mapped in family members and are used to
identify chromosomal regions that are co-inherited
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Table I. Major chromosomal locations with prime candidate genes
Chromosomal Candidate gene Function Association
location obtained
5q31.1-33.3 IL3, IL4, IL5, IL13, IgE class BHR, asthma,
IL9, CSF2, CD14 switching, atopy
eosinophil,
basophil and mast
cell maturation
ADRB2 G-protein Total IgE, BHR,
receptor Asthma, atopy
GRL Modulates Asthma, atopy
inflammation
6p2l.3 HLAD Antigen Specific IgE, IgE
presentation
TNF-a Mediates Asthma
inflammation
11q13 FceRIb Signal BHR, asthma, IgE,
transduction high eosinophils counts,
allergic dermatitis,
atopy
FGF3 Cellular
proliferation
12q14.3-24.1 IFN-g Inhibits IL4 Total IgE, BHR,
production asthma, atopy
SCF Produces IL4
NFYb Upregulates IL4
transcription
STAT6 Cytokine
transcription
factor
14q11.2-13 TCR-a, TCR-d Interacts with BHR, asthma, IgE
MHC complex
Activates
NFKb-1 immunoregulator
y genes
16pl2.1-11.2 IL4RA Signal Atopy, IgE
transduction and
activation
2q33 CD28, CTLA4 Antigen Atopy, asthma
presentation
20p13 ADAM33 Membrane Asthma
anchored
metalloprotease
BHR, bronchial hyper responsiveness
with a particular phenotype such as asthma,
bronchial hyperresponsiveness (BHR), or a positive
SPT. The data gathered from these studies where
the linkage has been verified in at least two
populations, have been summarised (Table II).
Attempts are underway to locate the genes in these
regions by fine mapping. ADAM33 is an important
gene located on 20p13 identified as a result of such
fine mapping63.
Contribution of environment to the pathogenesis
of asthma
In addition to genes, environmental factors, such
as allergens, food, childhood viral infection etc., also
play significant roles in causing asthma. The
incidence of asthma is rising with an alarming rate
in developed as well as in the developing countries.
It has been postulated that the immune deviation
resulting in asthma takes place much earlier in
utero74. Depending on the genetic status of the
mother during pregnancy and exposure to various
allergens, it is possible that the child may be born
with an intrinsic propensity to be atopic.
Genetically predisposed children when exposed
to environmental allergens develop asthma even in
very early phase of life75. Evidence of polymorphism
in the CD14 (LPS receptor) gene supports this
hypothesis41. In a recent study conducted in Canada,
it has been shown that daily visits to a local hospital
due to asthma increased significantly with increases
in level of pollens and pollution in the air76.
Similarly, in a study carried out in US, it has been
shown that with increase in air pollution levels in
Cincinatti, Cleveland and Columbus, the visits to
the asthma clinic increased significantly77. In a study
carried out in Palestinian children it has been shown
that familial atopic diseases are predictors of asthma
in children, however the indoor environment, such
as the presence of cats, dogs, etc., also play a major
role78.
In contrast, it has also been shown that the
prevalence of asthma in the western countries is
increasing even though the environment is cleaner
than earlier79,80. For example, the incidence of atopic
disorders including asthma in East Berlin increased
after the unification of Germany81-84. Similarly,
many surveys have identified an inverse relationship
between prior microbial exposure and the
development of atopy79. Further, it has been seen
that respiratory allergy appears less frequently in
people exposed to orofaecal and food-borne
microbes. Thus, improved hygiene, early infection
and antibiotic use, and semi-sterilized diet may
facilitate atopy by influencing exposure to
commensals and pathogens that stimulate cell
populations such as gut associated lymphoid
tissue85,86 . It is, therefore, proposed (hygiene
hypothesis) that the cleaner environment in the
western countries is not favourable for providing
signals for Thl development, especially in children
born of atopic parents79.
The underlying reason of these apparently
contradictory observations is not understood as yet.
Nevertheless, it seems very likely that environment
is only a triggering factor. A genetically predisposed
individual will develop the disorder anyway once
the ‘proper’ environmental exposure is provided
irrespective of the specific nature of the trigger.
Therefore, the identification of the environmental
factors that trigger asthma offers the possibility of
prevention of disease.
Current mode of asthma therapy
A large number of drugs are now available
(Table III), which help to control the signs and
symptoms of asthma87,88. The anti-leukotrines are
the newest class of anti-asthmatic drugs available.
Although, they do not provide any quick relief, they
help to control the symptoms of asthma in the long-
term.
Despite the introduction of such new agents,
corticosteriods are the anti-inflammatory drugs of
choice for the majority in the treatment of asthma89.
Both intravenous and oral forms are available and
are equally effective in the treatment of mild to
severe asthma89,90. However, when inhaled, the dose
is not sufficient to cause complete relief. Moreover,
the therapy is associated with side effects like
kidney, liver failure, increased hunger, compromised
immune system, high blood pressure, etc .
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Table II. Major chromosomal locations identified in various genome-wide scans in various populations
Chromosome Location Study Sample Phenotypes Statistical LOD
population size method/ score/
Programme used P value
1p D1S468 Hutterites64 693 Inbred Strict asthma LR (c2)/TDT P=0.0002
1p36.2 Japanese4 67 ASP Severe allergic GENEHUNTER P<0.002
rhinitis,
Total IgE P<0.002
2p D2S1780 Chinese6 2551 individuals Slope BHR Unified Haseman P=0.00002
Elston method
2q D2S2944 Hutterites64 693 Inbred SPT cockroach LR(c2)/TDT P=0.00004
D2S116 German65 156 ASP Total IgE GENEHUNTER P=0.0016
173-210 cM Dutch11,66 1174 individuals Total IgE Linkage LOD=1.96
from pter Eosinophils LOD=1.49
3p D3S3564 Hutterites64 693 Inbred Loose asthma LR (c2)/TDT P=0.00004
3p24.1 Japanese4 67 ASP Total IgE GENEHUNTER P<0.001
4q D4S1467 Chinese6 2551 individuals SPT Unified Haseman P=0.0003
4q24-27 Danish67 33 ASP Allergic rhinitis MAPMAKER/SIBS LOD=2.83
D4S2417 Japanese68 65 ASP Mite sensitive MAPMAKER/SIBS MLS=2.7
-D4S408 asthma
D4S426 Busselton69 172 ASP Slope BHR Haseman- P<0.0005
Elston sib pair
Technique
5p D5S268 French70 297 ASP Slope BHR GENEHUNTER P=0.001
D5S1470 Hutterites64 693 Inbred BHR LR (c2)/TDT P=0.001
5q D5S820 Japanese68 65 ASP Mite-sensitive MAPMAKER/SIBS MLS=4.8
asthma
D5S2014 Hutterites64 693 Inbred Asthma symptoms LR (c2)/TDT P=0.0009
130-172 cM Dutch11,66 1174 individuals Total IgE Linkage LOD=2.73
from pter
5q33.1 Japanese4 67 ASP Total IgE GENEHUNTER P<0.001
6p D6S276 Busselton69 172 ASP Eosinophils, Haseman- P<0.0001
Atopy, Elston sib pair P<0.005
Total IgE Tehnique P<0.05
30-40 cM Caucasians71,72 CSGA Asthma Multi-point LOD=1.91
from pter (266 Families) analysis
D6S276 German65 156 ASP Total IgE, GENEHUNTER P=0.0012
D6S291 RAST P=0.0011
D6S426 Eosinophils, P=0.0005
D6S291 Asthma P=0.0081
D6S1959- Japanese68 65 ASP Mite-sensitive MAPMAKER/SIB MLS=2.1
D6S2439 asthma
7p D7S484 Busselton69 172 ASP BHR, Haseman- P<0.0005
D7S2250 Total IgE, Elston sib pair P<0.005
D7S484/ Eosinophils Technique P<0.05
D7S2250
Contd...
7p14-15 Finnish73 220 affected IgE, Asthma Non-parameteric P<0.0001
linkage
D7S484 French70 297 ASP Eosinophils GENEHUNTER P=0.002
7q 98-109 cM Dutch11,66 1174 individuals Total IgE, Linkage LOD=3.36
from pter SPT aeroallergens LOD=1.04
11q FCER1B Busselton69 172 ASP Skin test index, Haseman- P<0.00005
Total IgE Elston sib pair P<0.005
Technique
D11S2002 African- CSGA Asthma ASP two-locus LOD=2
American71,72 (266 families) analysis,
Conditional
analysis
12q D12S366 French70 297 ASP Eosinophils GENEHUNTER P=0.0003
D12S78- Japanese68 65 ASP Mite-sensitive MAPMAKER/SIBS MLS=1.9
D12S79 asthma
111-134 cM Dutch11,66 1174 individuals Total IgE Linkage LOD=2.46
from pter
12q24.2 Japanese4 67 ASP Total IgE GENEHUNTER P<0.001
13q D13S787 Hutterites64 693 Inbred Asthma symptoms LR (c2)/TDT P=0.0006
D13S175- Japanese68 65 ASP Mite-sensitive MAPMAKER/SIBS MLS=2.4/2.0
D13S217/ asthma
D13S153
6-45 cM Dutch11,66 1174 individuals Total IgE Linkage LOD=2.28
from pter SPT LOD=1.27
D13S153 Busselton69 172 ASP Atopy Haseman- P<0.001
Elston sib pair
Technique
D13S170 French70 297 ASP Eosinophils GENEHUNTER P=0.002
16p D16S412 Chinese6 2551 individuals Forced vital Unified Haseman P=0.0006
capacity Elston method
16p12.3 Japanese4 67 ASP RAST (orchard GENEHUNTER P<0.001
grass)
16q D16S289 Busselton69 172 ASP Total IgE, Haseman- P<0.0005
Slope BHR Elston sib pair P<0.05
Technique
D16S539 Hutterites64 693 Inbred SPT (molds) LR (c2)/TDT P=0.0008
17q D17S250 French70 297 ASP SPT, GENEHUNTER P=0.001
Asthma P=0.003
62-100 cM Dutch11,66 1174 individuals Eosinophils, Linkage LOD=1.97
from pter SPT (Mite) LOD=1.21
19q D19S900 Hutterites64 693 Inbred BHR LR (c2)/TDT P<0.001
D19S433 Chinese6 2551 individuals BHR Unified Haseman- P=0.002
Elston method
The numbers in superscript denote references
IgE, Immunoglobulin E; BHR, Bronchial hyperresponsiveness; SPT, Skin Prick Test; RAST, Radio allergo sorbent test; LR, Likelihood
ratio; TDT, Transmission disequilibrium test; ASP, Affected sib pair; CSGA, Collaborative Study on Genetics of Asthma;
LOD, Log of odds; pter, Genetic distance (cM) based on Marshfield map
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Additionally, in 25 per cent of the cases there may
be resistance to treatment with the intensity of side-
effects increasing.
Response to asthma therapy varies with individual’s
genetic make-up
Various clinical trials have shown that there is
considerable variation in the treatment response from
individual to individual. These differences may be
due to genetic variations between individuals along
with variable expression of metabolic enzymes and
receptors for drugs91. These factors contribute in the
varying efficacy of the treatment regime. For
example, patients with polymorphisms in the core
promoter of ALOX5 leading to decreased promoter
activity in vitro, have failed to respond to treatment
with ALOX5 inhibitors like ABT-76192. It has been
noted that the promoter of ALOX5 contains 3-6
copies of Sp-1 binding sites. Only individuals with
wild type ALOX5 promoter (5 Sp-1 binding sites in
both chromosomes) responded to the therapy,
whereas individual with mutant alleles (any other
combination other than 5) failed to show any
improvement of lung function when treated with
ABT-761. Thus scanning of the ALOX5 promoter
for Sp-1 binding sites will provide the opportunity
to administer the drug according to the genetic
make-up of the individual. Sanak and Szczeklik54
have described a polymorphism in the leukotriene
C4 synthase (LTC4S) promoter that resulted in
higher risk of asprin-induced asthma. This genetic
variant may also alter the response to treatment with
drugs directed against leukotrines. Similarly,
variations in the b2-adrenergic receptor (ADRB2)
does not lead to the loss of functionality of the
receptor, however, the response of patients to
treatment with drugs varies from individual to
individual93. Drysdale et al84 have demonstrated that
only a limited number of b2AR haplotypes can be
found in several ethnic groups94. Also, transfection
studies have shown that certain haplotypes were
associated with a better response to b2-agonist drugs.
Table III. Major classification for types of drugs used in asthma therapy
Drug type Mechanism of Route of Example
action administration
Bronchodialators Relax smooth
muscles in the
airways
Beta-adrenergics Inhaled, subcutaneous, Epinephrine,
oral Isoproteronol
Methyl-xanthines Oral/iv Theophylline/Amino-
phlline
Anti-cholinergics Inhaled only Atropine, Atrovent
Anti-Inflammatory Decrease cellular
drugs response of
inflammation
Corticosteroids
Oral; Intramuscular; Beclomethasone,
intravenous Dexamethasone
Mediator-release
inhibitors Inhaled only Nedocromil sodium
Anti-leukotrine
drugs Oral only
Future perspective
The goal of current therapy for asthma is to render
the patient as symptom-free as possible and to reduce
or eliminate the need for rescue therapy and
hospitalisation. Even with the availability of a large
range of drugs, most patients show considerable
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Table IV. Novel strategies for the inhibition and prevention of
asthma
Target Agent
Prenvention of T-cell activation Anti-CD4
CTLA4
Prevention of reversal
of Th2 expression
Inhibition of Th2 cytokines Anti-IL4
STAT6 inhibition
Anti-IL5
GATA inhibition
Anti-IL9
Soluble ILI3Ra
Promotion of Th1 cytokines IFN-g
IL12
IL18
Immunotherapy Specific
Immunotherapy
Peptide immunotherapy
Mycobacterium vaccae
vaccination CpG
Inhibition of downstream mediators
Anti-inflammatory cytokines IL10
IL1Ra
Inhibition of eosinophil CCR3 Antagaonist
migration and activation CCR3 Antisense
Met-RANTES
Blocking cell adhesion VLA4 inhibitor
molecules ICAM-1 inhibitor
IgE inhibition Monoclonal anti-IgE
(E25)
STAT, signal tranducer and activator of transcription; IFN,
Interferon; IL, Interleukin; CCR, chemokine receptor; Met-
RANTES, Methionine-regulated on activation, normal T cell
expressed and secrefed; VLA, very late antigen; ICAM,
Intercellular cell adhesion molecule; CTLA, cytotoxic T
lymphocyte antigen
heterogeneity in terms of the type and extent of
inflammatory response, response to environmental
triggers and degree of atopy95,96. A major challenge
in asthma therapy has therefore been the
identification of novel therapeutic targets, which are
safer and more specific in their action. The major
abnormality in asthma is the presence of activated
CD4+-Th2 cells, eosinophils and increased levels of
certain Th2 cytokines. These findings, therefore,
suggest that most asthmatics may benefit from an
approach that targets the mechanism of allergic
sensitisation and inflammation97,98. A few of these
novel strategies are listed in Table IV.
Recent advances in the techniques for the
synthesis and manufacture of monoclonal antibodies,
synthetic peptides and peptidomimetic small
molecules have increased the potential for the
creation of specific inhibitors of immune processes
in allergic inflammation97. While preliminary data
from studies on these agents appear promising, these
agents will have to endure rigorous evaluation of
efficacy, long-term safety and minimal side effects
along with cost effectiveness. The advancement in
the understanding of the genetic predisposition for
asthma in various ethnic populations is likely to
change its classification and future treatment. The
future will thus see an era of predictive and
preventive medicines with the marketing of tailor-
made medicines to suit the genetic make-up of
individuals.
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